
  
    
      
        
        The_DT devastating_JJ effects_NNS of_IN HIV_NNP infection_NN worldwide_NN are_VBP reason_NN enough_RB for_IN AIDS_NNP
        researchers_NNS to_TO grasp_VB at_IN thin_JJ rays_NNS of_IN hope_VBP ._. But_CC seldom_RB has_VBZ a_DT single_JJ anecdotal_JJ case_NN
        stimulated_VBN as_IN much_JJ hope_NN as_IN the_DT 1999_CD report_NN of_IN an_DT acutely_RB infected_JJ patient_NN who_WP appeared_VBD to_TO
        control_VB HIV_NNP replication_NN after_IN two_CD short_JJ treatment_NN interruptions_NNS [_NN 1_CD ]_NN ._. This_DT report_NN generated_VBD
        the_DT hypothesis_NNS that_IN early_JJ antiretroviral_NN treatment_NN (_( during_IN or_CC very_RB soon_RB after_IN symptomatic_JJ
        seroconversion_NN )_) allows_VBZ the_DT incompletely_RB damaged_VBN immune_JJ system_NN to_TO recover_VB and_CC respond_VB
        appropriately_RB to_TO virus_NN antigens_NNS during_IN treatment_NN interruptions_NNS ._. This_DT ,_, in_IN turn_NN ,_, according_VBG to_TO
        the_DT hypothesis_NNS ,_, leads_VBZ to_TO control_NN of_IN viral_JJ replication_NN by_IN a_DT healed_VBN and_CC appropriately_RB
        stimulated_VBN immune_JJ response_NN to_TO the_DT patient_NN 's_POS HIV_NNP infection_NN ._.
        Consistent_NNP with_IN this_DT hypothesis_NNS was_VBD the_DT prior_RB finding_VBG that_IN early_JJ antiretroviral_NN therapy_NN
        led_VBN to_TO induction_NN of_IN HIV-specific_NNP proliferative_JJ responses_NNS similar_JJ to_TO those_DT that_WDT had_VBD been_VBN
        observed_VBN in_IN patients_NNS with_IN long-term_JJ ,_, non-progressing_JJ HIV_NNP [_NN 2_CD ]_NN ._. This_DT led_VBN Rosenberg_NNP and_CC
        colleagues_NNS to_TO ask_VB whether_IN HIV-specific_NNP proliferative_JJ responses_NNS were_VBD a_DT necessary_JJ and_CC
        sufficient_JJ cause_NN of_IN long-term_JJ non-progression_JJ or_CC just_RB an_DT immunologic_JJ consequence_NN of_IN
        controlled_VBN virus_NN replication_NN ._. Their_PRP$ report_NN of_IN virologic_JJ control_NN in_IN patients_NNS who_WP interrupted_VBN
        therapy_NN after_IN early_JJ treatment_NN raised_VBD hope_VBP that_IN if_IN HIV_NNP infection_NN was_VBD treated_VBN early_JJ enough_RB ,_,
        the_DT immune_JJ system_NN could_MD be_VB repaired_VBN sufficiently_RB to_TO allow_VB for_IN long-term_JJ immunologic_JJ control_NN
        of_IN HIV_NNP replication_NN [_NN 3_CD ]_NN ._. Unfortunately_RB ,_, that_DT 's_VBZ where_WRB the_DT good_JJ news_NN ends_NNS ._.
      
      
        Enthusiasm_NNP Fades_NNP
        A_DT series_NN of_IN discoveries_NNS from_IN clinical_JJ trials_NNS began_VBD to_TO chip_NN away_RB at_IN the_DT enthusiasm_NN for_IN
        both_DT early_JJ treatment_NN of_IN HIV_NNP infection_NN and_CC supervised_JJ treatment_NN interruptions_NNS (_( STIs_NNP )_) as_IN a_DT
        way_NN to_TO boost_VB the_DT immune_JJ response_NN ._.
        Several_JJ small_JJ trials_NNS of_IN STIs_NNP in_IN chronically_RB infected_JJ patients_NNS were_VBD carried_VBN out_IN [_NN 4_CD ]_NN ,_,
        buoyed_VBN by_IN the_DT reasonable_JJ desire_NN of_IN patients_NNS for_IN respite_NN from_IN the_DT unpleasant_JJ side_NN effects_NNS of_IN
        the_DT drugs_NNS ._. These_DT trials_NNS gave_VBD disappointing_JJ results_NNS ,_, up_IN to_TO and_CC including_VBG the_DT emergence_NN of_IN
        antiretroviral_NN drug_NN resistance_NN in_IN patients_NNS randomized_JJ to_TO receive_VB STIs_NNP ._. HIV-specific_NNP immune_JJ
        responses_NNS did_VBD increase_NN off_IN therapy_NN ,_, but_CC so_RB did_VBD viral_JJ loads_NNS ._. The_DT so-called_JJ immune_JJ boosting_VBG
        probably_RB reflected_VBD an_DT immune_JJ response_NN to_TO greater_JJR viral_JJ antigen_NN load_NN but_CC did_VBD not_RB represent_VB
        constructive_JJ immune_JJ enhancement_NN ._.
        Larger_NNP trials_NNS clearly_RB showed_VBD that_IN STIs_NNP were_VBD of_IN little_JJ if_IN any_DT benefit_NN in_IN chronic_JJ
        infection_NN and_CC that_IN when_WRB therapy_NN was_VBD stopped_VBN ,_, viral_JJ loads_NNS invariably_RB returned_VBD to_TO
        pre-treatment_JJ levels_NNS [_NN 5_CD ]_NN ._. Other_JJ studies_NNS indicated_VBD that_IN HIV-specific_NNP CD_NNP 4_CD +_NN T_NN cells_NNS were_VBD being_VBG
        preferentially_RB infected_JJ ,_, often_RB massively_RB ,_, during_IN treatment_NN interruptions_NNS [_NN 6_CD ]_NN ,_, and_CC that_IN
        proliferative_JJ responses_NNS were_VBD more_RBR likely_JJ to_TO be_VB a_DT consequence—rather_NN than_IN a_DT cause—of_NN
        decreased_VBD HIV_NNP replication_NN [_NN 7_CD ]_NN ._. Despite_IN multiple_JJ attempts_NNS ,_, early_JJ reports_NNS of_IN an_DT inverse_NN
        correlation_NN between_IN simple_JJ HIV-specific_NNP T_NN cell_NN responses_NNS and_CC virologic_JJ control_NN were_VBD not_RB
        confirmed_VBN [_NN 8_CD ]_NN ._. Where_WRB complex_JJ T_NN cell_NN functions_NNS did_VBD show_NN such_JJ a_DT correlation_NN ,_, the_DT data_NNS
        indicated_VBD that_IN viral_JJ replication_NN was_VBD adversely_RB affecting_VBG the_DT character_NN of_IN the_DT T_NN cell_NN immune_JJ
        response_NN to_TO HIV_NNP ,_, and_CC not_RB the_DT other_JJ way_NN around_IN [_NN 9_CD ]_NN ._. Thus_RB ,_, no_DT evidence_NN of_IN “ immune_JJ boosting_VBG”
        during_IN STIs_NNP and_CC subsequent_JJ viral_JJ control_NN in_IN the_DT absence_NN of_IN antiretroviral_NN drugs_NNS was_VBD ever_RB
        established_VBN ._. Finally_RB ,_, one_CD of_IN the_DT acutely_RB treated_VBN patients_NNS within_IN Rosenberg_NNP 's_POS cohort_NN became_VBD
        superinfected_JJ with_IN a_DT second_JJ strain_NN of_IN HIV_NNP despite_IN excellent_JJ control_NN of_IN viral_JJ replication_NN
        and_CC significant_JJ recognition_NN of_IN the_DT superinfecting_VBG strain_NN by_IN the_DT pre-existing_JJ T_NN cell_NN
        response_NN [_NN 10_CD ]_NN ._.
      
      
        New_NNP Findings_NNP
        Now_RB comes_VBZ a_DT study_NN in_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP that_WDT found_VBD that_IN in_IN 14_CD patients_NNS who_WP were_VBD treated_VBN early_JJ and_CC
        who_WP had_VBD controlled_VBN viral_JJ loads_NNS for_IN at_IN least_JJS 90_CD days_NNS ,_, the_DT virologic_JJ control_NN was_VBD only_RB
        transient_JJ [_NN 11_CD ]_NN ._. While_IN one_PRP could_MD look_VB at_IN this_DT as_IN a_DT glass_NN half_JJ full—these_NN patients_NNS achieved_VBD a_DT
        reasonable_JJ period_NN of_IN time_NN off_IN antiretroviral_NN therapy—closer_NN scrutiny_NN of_IN the_DT data_NNS limits_NNS
        this_DT view_NN ._.
        There_EX was_VBD a_DT disconnect_VB between_IN the_DT low_JJ viral_JJ loads_NNS and_CC an_DT unexpectedly_RB high_JJ rate_NN of_IN CD_NNP 4_CD +_NN
        T_NN cell_NN decline_NN in_IN several_JJ patients_NNS ._. While_IN the_DT small_JJ number_NN of_IN patients_NNS and_CC the_DT single-arm_JJ
        nature_NN of_IN the_DT study_NN preclude_VB definitive_JJ comparisons_NNS ,_, it_PRP is_VBZ possible_JJ that_IN the_DT early_JJ
        treatment_NN and_CC STIs_NNP did_VBD not_RB result_VB in_IN a_DT delay_NN in_IN CD_NNP 4_CD +_NN T_NN cell_NN decline_NN (_( and_CC ,_, therefore_RB ,_,
        initiation_NN of_IN antiretroviral_NN therapy_NN )_) beyond_IN what_WP would_MD have_VB occurred_VBN had_VBN the_DT patients_NNS
        received_VBD no_DT early_JJ treatment_NN ._.
      
      
        Implications_NNP of_IN the_DT Study_NNP
        This_DT study_NN raises_VBZ important_JJ questions_NNS in_IN our_PRP$ understanding_NN of_IN HIV_NNP pathogenesis_NNS ,_,
        treatment_NN ,_, and_CC vaccine_NN development_NN ._.
        First_LS ,_, why_WRB is_VBZ it_PRP that_IN early_JJ antiretroviral_NN treatment_NN ,_, even_RB if_IN it_PRP does_VBZ lead_VB to_TO better_JJR
        control_NN of_IN viral_JJ replication_NN ,_, does_VBZ not_RB protect_VB against_IN CD_NNP 4_CD +_NN T_NN cell_NN depletion_NN ?_. It_PRP is_VBZ
        possible_JJ that_IN by_IN the_DT time_NN patients_NNS present_JJ with_IN acute_JJ retroviral_NN syndrome_NN their_PRP$ CD_NNP 4_CD +_NN T_NN cell_NN
        reserves_NNS (_( in_IN gut_NN and_CC lymphoid_NN tissues_NNS )_) have_VBP been_VBN severely_RB depleted_VBN ,_, despite_IN the_DT fairly_RB
        normal_JJ CD_NNP 4_CD +_NN profile_NN of_IN their_PRP$ peripheral_JJ blood_NN ._. Thus_RB ,_, even_RB low-level_JJ viral_JJ replication_NN is_VBZ
        then_RB sufficient_JJ to_TO deplete_VB the_DT remaining_VBG central_JJ and_CC peripheral_JJ reserves_NNS [_NN 12_CD ]_NN ._.
        Second_JJ ,_, how_WRB do_VBP these_DT findings_NNS affect_VBP treatment_NN guidelines_NNS during_IN acute_JJ infection_NN ?_. None_NN
        of_IN the_DT current_JJ treatment_NN guidelines_NNS in_IN either_DT resource-rich_JJ or_CC resource-poor_JJ settings_NNS
        recommend_VBP early_JJ antiretroviral_NN therapy_NN ._. In_IN the_DT light_NN of_IN these_DT new_JJ data_NN [_NN 11_CD ]_NN ,_, there_EX does_VBZ not_RB
        appear_VB to_TO be_VB a_DT rationale_NN for_IN early_JJ antiretroviral_NN therapy_NN in_IN the_DT absence_NN of_IN a_DT clinical_JJ
        trial_NN to_TO assess_VB other_JJ interventions_NNS in_IN concert_NN with_IN early_JJ therapy_NN ._. The_DT use_NN of_IN therapeutic_JJ
        vaccination_NN is_VBZ an_DT obvious_JJ intervention_NN that_WDT still_RB needs_VBZ to_TO be_VB tested_VBN ,_, despite_IN limited_JJ
        efficacy_NN results_NNS in_IN treated_VBN chronic_JJ infection_NN ._. As_IN such_JJ ,_, practice_NN guidelines_NNS should_MD continue_VB
        to_TO caution_VB against_IN early_JJ treatment_NN unless_IN associated_VBN with_IN a_DT randomized_JJ clinical_JJ trial_NN ._.
        Finally_RB ,_, is_VBZ this_DT good_JJ or_CC bad_JJ news_NN for_IN HIV_NNP vaccine_NN development_NN ?_. Since_IN most_JJS current_JJ
        vaccine_NN strategies_NNS are_VBP based_VBN upon_IN the_DT hypothesis_NNS that_WDT induction_NN of_IN T_NN cell_NN immunity_NN will_MD
        lead_VB to_TO control_NN of_IN viral_JJ replication_NN ,_, it_PRP is_VBZ difficult_JJ to_TO be_VB optimistic_JJ when_WRB a_DT strong_JJ and_CC
        broad_JJ immune_JJ response_NN is_VBZ unable_JJ to_TO prevent_VB disease_NN progression_NN ._. However_RB ,_, one_PRP must_MD recall_VB
        that_IN phenotypic_JJ and_CC functional_JJ assessments_NNS of_IN HIV-specific_NNP T_NN cell_NN responses_NNS ,_, even_RB in_IN
        antiretroviral-treated_JJ patients_NNS ,_, show_NN that_IN these_DT responses_NNS clearly_RB differ_VBP from_IN responses_NNS
        against_IN viruses_NNS that_WDT are_VBP normally_RB cleared_VBN or_CC controlled_VBN by_IN the_DT immune_JJ system_NN [_NN 9_CD ]_NN ._.
        Therefore_RB ,_, the_DT T_NN cell_NN responses_NNS in_IN the_DT patients_NNS treated_VBN for_IN acute_JJ HIV_NNP infection_NN in_IN Kaufmann_NNP
        et_CC al_NN ._. 's_POS study_NN were_VBD induced_VBN upon_IN a_DT dramatically_RB altered_VBN immune_JJ background_NN ._. It_PRP remains_VBZ to_TO be_VB
        determined_VBN how_WRB much_JJ this_DT adversely_RB affects_VBZ the_DT HIV-specific_NNP immune_JJ response_NN ,_, and_CC whether_IN an_DT
        immune_JJ response_NN generated_VBN by_IN vaccination_NN 
        before_IN any_DT HIV_NNP replication_NN (_( a_DT prophylactic_JJ vaccine_NN )_) might_MD be_VB better_RBR able_JJ
        to_TO control_VB virus_NN replication_NN ._. Far_NNP be_VB it_PRP for_IN us_PRP to_TO stop_VB grasping_VBG at_IN rays_NNS of_IN hope_VBP ._.
      
    
  
